Delivering Advanced Therapeutics
Critical Pharmaceuticals is developing a pipeline of unique biological drug products utilizing its proprietary CriticalSorb and CriticalMix drug delivery technologies.
CP024 nasal growth hormone (hGH or somatropin) is in phase 1 clinical development for growth hormone deficiency in children and adults where our intranasal spray has shown comparable activity (IGF-1 induction) to an injection of marketed drug. CP024 uses Critical Pharmaceuticals CriticalSorb drug delivery technology.
CP046 nasal teriparatide (parathyroid hormone or PTH 1-34) for the treatment of osteoporosis is being developed in collaboration with the University of Nottingham and uses Critical Pharmaceuticals CriticalSorb technology.
CP016 is a long acting injection of human growth hormone (hGH or somatropin) in preclinical development for the treatment of growth hormone deficiency in children and adults that uses Critical Pharmaceuticals CriticalMix technology.
CP018 is a long acting injection of risperidone in formulation development for the treatment of schizophrenia and other psychiatric disorders that uses Critical Pharmaceuticals CriticalMix technology.